Lexeo Therapeutics (NASDAQ:LXEO) reported an insider sale by its chief executive officer, Richard Nolan Townsend, who sold 55,000 shares of common stock on April 6, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The shares changed hands at a weighted average price of $5.6934, producing a total transaction value of $313,137. The sale price spanned a range from $5.56 to $5.94. After the transaction, Townsend is recorded as directly owning 340,106 shares of Lexeo Therapeutics, which includes 261,349 restricted stock units.
Market movement since the sale shows the stock trading at $6.30, higher than the $5.72 close immediately before the sale. Despite the recent uptick, shares are still down 42% year-to-date, while the company has posted a 222% gain over the prior 12 months.
According to InvestingPro analysis, LXEO currently trades above its Fair Value and is listed among the most overvalued stocks. The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025.
Concurrent with the disclosure of the insider transaction, Lexeo presented clinical trial data for its AAV-based gene therapy candidates, LX2006 and LX2020, at the American College of Cardiology conference. Those disclosures were accompanied by analyst commentary and rating actions.
Cantor Fitzgerald reiterated an Overweight rating with a $19.00 price target, citing efficacy and safety data from the trials. Oppenheimer likewise maintained an Outperform rating with a $20.00 price target, pointing to clear efficacy signals from the LX2020 study in PKP2-associated arrhythmogenic cardiomyopathy and noting safety observations described as unconcerning.
Separately, Lexeo announced executive changes. Narinder Bhalla, MD, was appointed Chief Medical Officer. José Manuel Otero, PhD, was promoted from Chief Technical Officer to Chief Operating Officer, with an annual base salary set at $510,000.
The company and analysts have emphasized the clinical readouts, but the filings also note that some investors have found aspects of the trial data difficult to interpret, specifically results related to premature ventricular contractions and non-sustained ventricular tachycardias.
These items - the insider sale under a pre-arranged plan, the presentation of clinical data, analyst endorsements, and leadership appointments - together outline ongoing developments at Lexeo Therapeutics as it progresses through clinical programs and corporate reorganization.